HTTIF (HighTide Therapeutics) Gross Profit: $0.00 Mil (TTM As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Gross Profit?

HighTide Therapeutics HTTIF 14 Gross Profit is $0.00 Mil as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

HighTide Therapeutics's gross profit for the six months ended in Dec. 2025 was $0.00 Mil. HighTide Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. HighTide Therapeutics's gross profit for the six months ended in Dec. 2025 was $0.00 Mil. HighTide Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, HighTide Therapeutics's Gross Margin % for the quarter that ended in Dec. 2025 was N/A%.

HighTide Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage


HighTide Therapeutics  (OTCPK:HTTIF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

HighTide Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage


HighTide Therapeutics Gross Profit Related Terms


HighTide Therapeutics Gross Profit Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Gross Profit Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Gross Profit
0.00 0.00 0.00 0.00 0.00

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Gross Profit Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

HTTIF vs VRTX, REGN, ALNY: Gross Profit Comparison

For the Biotechnology subindustry, HighTide Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics Gross Profit vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Gross Profit falls into.


HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Gross Profit is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

HighTide Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2025 is calculated as

Gross Profit (A: Dec. 2025 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

HighTide Therapeutics's Gross Profit for the quarter that ended in Dec. 2025 is calculated as

Gross Profit (Q: Dec. 2025 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

HighTide Therapeutics's Gross Margin % for the quarter that ended in Dec. 2025 is calculated as

Gross Margin % (Q: Dec. 2025 )=Gross Profit (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Profit →
What does a Gross Profit of $0.00 Mil mean?
HighTide Therapeutics (HTTIF) has a Gross Profit of $0.00 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' Gross Profit too high?
HighTide Therapeutics' current Gross Profit is $0.00 Mil. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Gross Profit compare to VRTX and REGN?
HighTide Therapeutics' Gross Profit of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current Gross Profit is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Gross Profit of $0.00 Mil. The current Gross Profit is $0.00 Mil. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Gross Profit is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price